Armata says inhaled phage candidate AP-PA02 completes Phase 2 trials in cystic fibrosis, bronchiectasis patients
ARMP•Broader structural biology efforts
Work also signals expansion of the company’s structural biology efforts to proprietary Staphylococcus aureus phages.
AP-PA02 Phase 2 program and publication
Armata Pharmaceuticals disclosed a peer-reviewed publication on Sept. 3, 2026, tied to its AP-PA02 inhaled bacteriophage program.
Results were already presented in the paper, detailing how a key Pseudomonas-targeting phage stays stable pre-infection, then delivers its genome efficiently.
Development rationale for antibacterial work
Findings aim to support next-generation antibacterial development, reinforcing the program’s rationale following completed Phase 2 studies in CF and NCFB patients.
